Nxera Pharma

Tokyo, Japan Founded: 1990 • Age: 36 yrs Listed
GPCR-targeted therapeutics are developed for various diseases.

About Nxera Pharma

Nxera Pharma is a publicly listed company based in Tokyo (Japan) founded in 1990. GPCR-targeted therapeutics are developed for various diseases. It operates on a HealthTech model. The company has 374 employees. Its website nxera.life draws about 16 thousand monthly visits. Nxera Pharma offers products and services including HTL0039732. Its focus areas include Pharmaceuticals and Biotechnology.

Company details

Nxera Pharma is engaged in the development of innovative medicines aimed at transforming lives. The company is involved in the healthcare sector, specifically in pharmaceuticals and biotechnology. Emphasis is placed on accelerating drug development through investment in science and technology. Solutions are pursued to achieve breakthroughs in treatment, particularly in areas like cancer immunotherapy. Structure-based drug design is revolutionized by embracing advanced technology. Partnerships are sought to drive once-in-a-generation discoveries for patients in need.

  • Headquarters Tokyo, Japan
  • Employees 374
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website nxera.life
  • Social LinkedIn X YouTube
  • Legal Name Nxera Pharma Co., Ltd.
Key Metrics
  • Annual Revenue
    $188.99 M (USD)
    2.71
    as on Dec 31, 2025
  • Net Profit
    -$79.98 M (USD)
    -158.99
    as on Dec 31, 2025
  • EBITDA
    -$23.68 M (USD)
    -168.84
    as on Dec 31, 2025
  • Latest Funding Round
    $53.11M (USD), Post-IPO

    Nov 2023

  • Investors
  • Employee Count
    374

Products & Services of Nxera Pharma

Nxera Pharma offers a comprehensive portfolio of products and services, including HTL0039732.

HTL0039732
Cancer Immunotherapy

Investigational treatment developed for cancer immunotherapy in trials.

Apps and channels of Nxera Pharma

its YouTube channel Nxera has 150 subscribers.

Nxera
YouTube 150 subscribers Other
Open channel

Funding Insights of Nxera Pharma

  • Total Rounds 2
  • Last Round Post-IPO β€” $53.11M
  • First Round $363,317

    (Sep 2021)

  • Investors Count 2

All 2 funding rounds of Nxera Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2023$53.11MPost-IPO––
Sep 2021$363,317Grant––
Valuation history

2 investors in total: 2 institutional.

Investors in Nxera Pharma

Nxera Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and OPF1 fund.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Premium access

Investor details for Nxera Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Nxera Pharma

65 people are tracked at Nxera Pharma (33 in leadership, 32 in team); the tracked headcount is 374.

NameRoleGroup
Sophie Bradley
Director (translational Biology)Leadership
Jayesh Patel
Director, Protein EngineeringLeadership
Mathieu Rappas
Senior Director Protein SciencesLeadership
Nigel Swain
Vice President, Head Of DiscoveryLeadership
Giselle Wiggin
Senior DirectorLeadership
Chris Cargill
President and Chief Executive OfficerLeadership
Greg Sissons
Director, Head Of ProcurementLeadership
Paul S.
Vice President Enterprise Portfolio ManagementLeadership
Toshihiro Maeda
Chief Operating Officer And President Of Nxera Pharma JapanLeadership
Marianne Muldbjerg
Head Of Site OperationsLeadership
Lara Kitchin
Legal DirectorLeadership
Marcus Messenger
Head Of Business DevelopmentLeadership
Claire Teague
Director, Head Of Translational Biomarkers & BioinformaticsLeadership
Candelle Chong
Executive Vice President, Chief Of StaffLeadership
Gerard Collins
Human Resources DirectorLeadership
Catherine Tighe
Associate DirectorLeadership
Mariko Nakafuji
Chief Legal OfficerLeadership
Michelle Fairey Assoc Cipd
Senior HR Business PartnerLeadership
Helen Carberry
Head Of Human ResourcesLeadership
Steve Watson
Senior Director Of Chemistry At Nxera PharmaLeadership

45 more people are available in the full profile.

Premium access

Complete people profiles for Nxera Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Nxera Pharma

Nxera Pharma is a publicly listed company on the TSE with ticker symbol 4565 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date08 Feb 2019
  • Listed onFRA: JSS
  • Listed entityNxera Pharma Co., Ltd.
  • Exchange sectorHealth technology
  • ISINJP3431300007
  • Share price1,183.00 JPY (-3.03% on the day) · 2026-10-14
  • Market capitalisation112,989,012,909.00 JPY
  • EPS (diluted, trailing year)-88.88 JPY
  • Volume (last session)835,900

Financials of Nxera Pharma

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
202529.61B JPY-12.53B JPY-3.71B JPY
202428.84B JPY-4.84B JPY-1.38B JPY
202312.77B JPY-7.19B JPY-6.58B JPY
202215.57B JPY382.0M JPY4.16B JPY
202117.71B JPY1.02B JPY8.19B JPY
Premium access

Detailed financial statements for Nxera Pharma

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Nxera Pharma

4 dated milestones of Nxera Pharma across 33 years, from founding to its latest funding, stage changes and deals.

  1. Founded Nxera Pharma is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $363K.
  4. Funding Latest funding round, Post-IPO, of $53.1M.

Web traffic of Nxera Pharma

The website of Nxera Pharma (nxera.life) receives about 16.3K visits a month and ranks #1,116,988 among all websites worldwide, #1,383 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    16.3K

    ▼ 15.4% vs previous month

  • Unique visitors
    8.2K

    per month

  • Global rank
    #1,116,988

    among all websites

  • Category rank
    #1,383

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Nxera Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
answers.ten-navi.com
answers.ten-navi.com
100%
#1,204,032–
boehringer-ingelheim.com
60%
1.6M#39,825View details
fiercepharma.com
40%
#124,066View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Nxera Pharma

Premium access

Complete news archive for Nxera Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nxera Pharma

Nxera Pharma was founded in 1990 and raised its 1st funding round 31 years after it was founded.

Nxera Pharma is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.

Nxera Pharma has 374 employees.

Annual revenue of Nxera Pharma is $188.99M as on Dec 31, 2025.

Nxera Pharma is engaged in the development of innovative medicines aimed at transforming lives. The company is involved in the healthcare sector, specifically in pharmaceuticals and biotechnology. Emphasis is placed on accelerating drug development through investment in science and technology. Solutions are pursued to achieve breakthroughs in treatment, particularly in areas like cancer immunotherapy. Structure-based drug design is revolutionized by embracing advanced technology. Partnerships are sought to drive once-in-a-generation discoveries for patients in need.

Nxera Pharma offers HTL0039732.

Yes, Nxera Pharma is publicly traded on TSE under the ticker symbol 4565.

Nxera Pharma has 2 investors. Key investors include European Union, and OPF1 fund.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available